LifeTime Conference 2.0 – June 16-17, 2021       REGISTER HERE

Berlin Summer Meeting 2021 – June 18, 2021


On behalf of the LifeTime community, we are delighted to announce the LifeTime Conference 2.0 on June 16-17, 2021. This second meeting about cell-based interceptive medicine brings together an exciting selection of international speakers, including selected short talks from abstracts. Moreover, this year’s meeting will be conjoined with the annual Berlin Summer Meeting on June 18th, organized by the Berlin Institute for Medical Systems Biology (BIMSB) at the Max Delbrück Center (MDC) – this year’s topic: “Innovative RNA”.


Please join us for an inspiring three days as we explore recent developments towards LifeTime’s goal of tracking, understanding and targeting cells for treatment of diseases. Please find the list of speakers on the attached poster. 


The events will be hosted by the MDC with the support of Single Cell Omics Germany (SCOG), a network funded by the Federal Ministry of Education and Research (BMBF).


Due to current restrictions, both the LifeTime Conference 2.0 and the Berlin Summer Meeting 2021 will be virtual meetings. However, if circumstances allow, we hope to switch to a hybrid mode. We will keep you updated!  


Information about registration, abstract submission and the detailed program will be announced in March on our website and Twitter channel.


We are very much looking forward to three days of excellent science, fruitful discussions and your contributions!


Sincerely yours and stay healthy,

Nikolaus Rajewsky (MDC, Berlin) & Geneviève Almouzni (Institut Curie, Paris)
– on behalf of the LifeTime Conference 2.0 Organizing Committee


UPDATE April 1: The registration for the LifeTime Conference 2.0 is now open.

– Abstract Deadline May 12

– Registration Deadline June 1

More Information on Berlin Summer Meeting 2021 – “Innovative RNA”:

This year’s Berlin Summer Meeting will be about bringing together (a) the latest breakthroughs in RNA basic research that may drive medical innovations of the future, and (b) RNA applications already on a path to enter the clinics, including RNA based drugs and vaccines against cancer, infection, or neurodegenerative diseases.  Besides the scientists and innovators, we will invite venture capital, policy makers, patient representatives, etc to join the discussion, thus creating a forum in which RNA goes from basic science all the way to medicine and innovation.